surmount 2 tirzepatide Efficacy and safety of once‐weekly in Japanese participants with type diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT‐2 trial - Yamauchi - 2025 SURMOUNT 2 offers new data

But in March, the FDA approved Wegovy to reduce cardiovascular risk in overweight people, after a clinical study showed the drug cut the risk of heart attacks and strokes by as much as 20 percent for overweight people with a history of heart disease

Side effects from Contrave typically occur in the first few weeks as your body adjusts to the medication

Semaglutide is most effective when combined with a nutritious diet and frequent exercise

Using expired medication can hinder your weight loss progress and increase the risk of injection-site infections

In addition, a study from the French Pharmacovigilance Database showed that compared with other antihyperglycemic agents, the use of GLP-1 analogs is associated with an increased risk of acute pancreatitis [16]